Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib, Venetoclax, and Azacitidine in MPN-AP/BP
NCT07679334Phase 1Not yet recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pacritinib in Myeloproliferative Neoplasm (MPN), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
pacritinib
03
Conditions
Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT07679334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07679334.